Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Paclitaxel 337pembrolizumab 333Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 240Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 170Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 119Prednisone 118Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Doxorubicin 98Leucovorin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 78Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Ibandronic Acid × Clear all
NCT01077817 2022-02-03

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

Organon and Co

Completed
684,815 enrolled 6 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT02739594 2016-07-22

COMPARE

Hoffmann-La Roche

Phase 3 Terminated
89 enrolled 17 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡